Seco-DUBA|cas:1227961-59-2|西域试剂

Seco-DUBA,95.81%

产品编号：Bellancom-132180A| CAS NO：1227961-59-2| 分子式：C₂₉H₂₃ClN₄O₄| 分子量：526.97

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-132180A	￥11800.00	杭州北京（现货）
Bellancom-132180A	￥26500.00	杭州北京（现货）
Bellancom-132180A	￥38500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Seco-DUBA

产品介绍

Seco-DUBA 是一种多卡霉素 (DUBA) 的前药，含有两个羟基，每个羟基都可以通过连接剂与抗体偶联。Seco-DUBA 可用于合成抗体-药物结合物 (ADCs)。

生物活性

Seco-DUBA is a duocarmycin (DUBA) prodrug containing two hydroxyl groups, which can each be used for coupling to an antibody via a linker. Seco-DUBA can be used in the synthesis of antibody-drug conjugates (ADCs).

体外研究

Seco-DUBA (SK-BR-3 cells; 0.0001 pM~0.01 nM; 144 hours) dose-dependent reduces cell viability and shows equally potent and efficacious as DUBA.
Seco-DUBA causes SK-BR-3 (IC₅₀=0.09), SK-OV-3 (IC₅₀=0.43), and SW620 (IC₅₀=0.09) cells to exhibit highly sensitive.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay

Cell Line:	SK-BR-3 cells
Concentration:	0.0001 pM~0.01 nM
Incubation Time:	144 hours
Result:	Dose-dependent reduced cell viability.

体内研究
(In Vivo)

Seco-DUBA (89 μg/kg; i.v.) is likely converted to DUBA almost instantaneously.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Wistar rats
Dosage:	89 μg/kg (Pharmacokinetic Analysis)
Administration:	I.v.
Result:	Likely converted to DUBA almost instantaneously.

体内研究

Seco-DUBA (89 μg/kg; i.v.) is likely converted to DUBA almost instantaneously.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Wistar rats
Dosage:	89 μg/kg (Pharmacokinetic Analysis)
Administration:	I.v.
Result:	Likely converted to DUBA almost instantaneously.

体内研究

Seco-DUBA (89 μg/kg; i.v.) is likely converted to DUBA almost instantaneously.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Wistar rats
Dosage:	89 μg/kg (Pharmacokinetic Analysis)
Administration:	I.v.
Result:	Likely converted to DUBA almost instantaneously.

性状

Solid

溶解性数据

In Vitro:

DMSO : 100 mg/mL (189.76 mM; ultrasonic and warming and heat to 60°C)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.8976 mL	9.4882 mL	18.9764 mL
5 mM	0.3795 mL	1.8976 mL	3.7953 mL
10 mM	0.1898 mL	0.9488 mL	1.8976 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (stored under nitrogen)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: 1 mg/mL (1.90 mM); Suspended solution; Need ultrasonic

此方案可获得 1 mg/mL (1.90 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。
以 1 mL 工作液为例，取 100 μL 10.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: 1 mg/mL (1.90 mM); Suspended solution; Need ultrasonic

此方案可获得 1 mg/mL (1.90 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。
以 1 mL 工作液为例，取 100 μL 10.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明